Misplaced Pages

Neosalvarsan: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editContent deleted Content addedVisualWikitext
Revision as of 18:54, 7 November 2024 editG3560 (talk | contribs)421 editsm capitalization← Previous edit Latest revision as of 18:58, 7 November 2024 edit undoG3560 (talk | contribs)421 editsm capitalization 
Line 38: Line 38:
}} }}


'''Neosalvarsan''' is a synthetic ] that is an ]. It became available in 1912 and superseded the more toxic and less water-soluble ] as an effective treatment for ]. Because both of these arsenicals carried considerable risk of side effects, they were replaced for this indication by ] in the 1940s. '''Neosalvarsan''' is a synthetic ] that is an ]. It became available in 1912 and superseded the more toxic and less water-soluble ] as an effective treatment for ]. Because both of these arsenicals carried considerable risk of side effects, they were replaced for this indication by ] in the 1940s.


Both salvarsan and neosalvarsan were developed in the laboratory of ] in ], ]. Their discoveries were the result of the first organized team effort to optimize the ] of a ] through systematic chemical modifications.<ref>{{cite journal |vauthors=Strebhardt K, Ullrich A |title=Paul Ehrlich's magic bullet concept: 100 years of progress |journal=Nat. Rev. Cancer |volume= 8|issue= 6|pages= 473–480|date=May 2008 |pmid=18469827 |doi=10.1038/nrc2394 |s2cid=30063909 }}</ref> This scheme is the basis for most modern ] research. Both salvarsan and neosalvarsan are ]s{{snd}}that is, they are ] into the active drug in the body. Both Salvarsan and Neosalvarsan were developed in the laboratory of ] in ], ]. Their discoveries were the result of the first organized team effort to optimize the ] of a ] through systematic chemical modifications.<ref>{{cite journal |vauthors=Strebhardt K, Ullrich A |title=Paul Ehrlich's magic bullet concept: 100 years of progress |journal=Nat. Rev. Cancer |volume= 8|issue= 6|pages= 473–480|date=May 2008 |pmid=18469827 |doi=10.1038/nrc2394 |s2cid=30063909 }}</ref> This scheme is the basis for most modern ] research. Both Salvarsan and Neosalvarsan are ]s{{snd}}that is, they are ] into the active drug in the body.


Although, like salvarsan, it was originally believed to contain an arsenic-arsenic double bond, this is now known to be incorrect for salvarsan.<ref>{{Cite journal|last1=Lloyd|first1=Nicholas C.|last2=Morgan|first2=Hugh W.|last3=Nicholson|first3=Brian K.|last4=Ronimus|first4=Ron S.|date=2005|title=The Composition of Ehrlich's Salvarsan: Resolution of a Century-Old Debate|journal=Angewandte Chemie International Edition|volume=44|issue=6|pages=941–944|doi=10.1002/anie.200461471|pmid=15624113|hdl=10289/207|issn=1521-3773|url=https://researchcommons.waikato.ac.nz/bitstream/10289/207/1/content.pdf|doi-access=free}}</ref> Presumably, neosalvarsan also exists as a mixture of differently sized rings with arsenic-arsenic single bonds. Although, like Salvarsan, it was originally believed to contain an arsenic-arsenic double bond, this is now known to be incorrect for Salvarsan.<ref>{{Cite journal|last1=Lloyd|first1=Nicholas C.|last2=Morgan|first2=Hugh W.|last3=Nicholson|first3=Brian K.|last4=Ronimus|first4=Ron S.|date=2005|title=The Composition of Ehrlich's Salvarsan: Resolution of a Century-Old Debate|journal=Angewandte Chemie International Edition|volume=44|issue=6|pages=941–944|doi=10.1002/anie.200461471|pmid=15624113|hdl=10289/207|issn=1521-3773|url=https://researchcommons.waikato.ac.nz/bitstream/10289/207/1/content.pdf|doi-access=free}}</ref> Presumably, Neosalvarsan also exists as a mixture of differently sized rings with arsenic-arsenic single bonds.


==References== ==References==

Latest revision as of 18:58, 7 November 2024

Neosalvarsan
Names
Other names Sodium 3,3'-diamino-4,4'-dihydroxyarsenobenzene-N-formaldehydesulfoxylate; Neoarsphenamine;914
Identifiers
CAS Number
3D model (JSmol)
ChemSpider
ECHA InfoCard 100.006.613 Edit this at Wikidata
PubChem CID
UNII
CompTox Dashboard (EPA)
InChI
  • InChI=1S/C13H14As2N2O4S.Na/c16-10-5-8(1-3-12(10)18)14-15-9-2-4-13(19)11(6-9)17-7-22(20)21;/h1-6,17-19H,7,16H2,(H,20,21);/q;+1/p-1Key: BGYSJUFVJUJSOL-UHFFFAOYSA-M
  • InChI=1/C13H14As2N2O4S.Na/c16-10-5-8(1-3-12(10)18)14-15-9-2-4-13(19)11(6-9)17-7-22(20)21;/h1-6,17-19H,7,16H2,(H,20,21);/q;+1/p-1Key: BGYSJUFVJUJSOL-REWHXWOFAO
SMILES
  • .S(=O)CNc2cc(/=/c1ccc(O)c(N)c1)ccc2O
Properties
Chemical formula C13H13As2N2NaO4S
Molar mass 466.15 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C , 100 kPa). checkY verify (what is  ?) Infobox references
Chemical compound

Neosalvarsan is a synthetic chemotherapeutic that is an organoarsenic compound. It became available in 1912 and superseded the more toxic and less water-soluble Salvarsan as an effective treatment for syphilis. Because both of these arsenicals carried considerable risk of side effects, they were replaced for this indication by penicillin in the 1940s.

Both Salvarsan and Neosalvarsan were developed in the laboratory of Paul Ehrlich in Frankfurt, Germany. Their discoveries were the result of the first organized team effort to optimize the biological activity of a lead compound through systematic chemical modifications. This scheme is the basis for most modern pharmaceutical research. Both Salvarsan and Neosalvarsan are prodrugs – that is, they are metabolised into the active drug in the body.

Although, like Salvarsan, it was originally believed to contain an arsenic-arsenic double bond, this is now known to be incorrect for Salvarsan. Presumably, Neosalvarsan also exists as a mixture of differently sized rings with arsenic-arsenic single bonds.

References

  1. Strebhardt K, Ullrich A (May 2008). "Paul Ehrlich's magic bullet concept: 100 years of progress". Nat. Rev. Cancer. 8 (6): 473–480. doi:10.1038/nrc2394. PMID 18469827. S2CID 30063909.
  2. Lloyd, Nicholas C.; Morgan, Hugh W.; Nicholson, Brian K.; Ronimus, Ron S. (2005). "The Composition of Ehrlich's Salvarsan: Resolution of a Century-Old Debate" (PDF). Angewandte Chemie International Edition. 44 (6): 941–944. doi:10.1002/anie.200461471. hdl:10289/207. ISSN 1521-3773. PMID 15624113.
Categories: